Antiretroviral preexposure prophylaxis (PrEP; emtricitabine and tenofovir 
disoproxil fumarate [Truvada]) prevents HIV without penalizing sexual pleasure, 
and may even enhance pleasure (e.g., by reducing HIV-related anxiety). However, 
concern about sexual risk behavior increasing with PrEP use (risk compensation) 
and corresponding stereotypes of promiscuity may undermine PrEP's preventive 
potential. In this commentary, we review literature on sexual behavior change 
accompanying PrEP use, discuss risk compensation concerns and the "Truvada 
whore" stereotype as PrEP barriers, question the appropriateness of restricting 
PrEP access because of risk compensation, and consider sexual pleasure as a 
benefit of PrEP, an acceptable motive for seeking PrEP, and a core element of 
health. It is essential for science to trump stereotypes and sex-negative 
messaging in guiding decision-making affecting PrEP access and uptake.